RA Capital Files WVE Form 4 Disclosing RSUs, Options and 18.2M Shares
Rhea-AI Filing Summary
Form 4 filed for Wave Life Sciences (WVE) reports director compensation awards and large Fund holdings. On 08/11/2025 RA Capital entities and affiliated individuals disclosed awards and holdings related to Dr. Peter Kolchinsky, a director. The filing shows a grant of 12,700 restricted share units (RSUs) and an award of 76,200 share options with an $8.105 exercise price. The RSUs and options vest on the earlier of the issuer's 2026 annual general meeting or August 11, 2026, and the options expire August 11, 2030.
The filing further reports 28,815 shares beneficially owned following the reported transaction(s) (indirect) and that RA Capital Healthcare Fund, L.P. directly holds 18,202,009 shares. Footnotes state the RSUs/options are held for the benefit of the Fund and that the reporting parties disclaim beneficial ownership except for pecuniary interest.
Positive
- Director equity awards align incentives: 12,700 RSUs and 76,200 options granted to a director link compensation to shareholder outcomes
- Large disclosed fund stake: RA Capital Healthcare Fund, L.P. directly holds 18,202,009 shares, providing clear transparency on ownership
Negative
- None.
Insights
TL;DR Director received equity awards and the adviser-affiliated fund holds a large stake; disclosure is routine and aligns director incentives with shareholders.
The Form 4 documents non-employee director compensation via 12,700 RSUs and 76,200 options granted on 08/11/2025 with standard vesting tied to the 2026 AGM or August 11, 2026. The filing explicitly states these awards are held for the benefit of RA Capital Healthcare Fund, L.P., and that net proceeds will offset advisory fees. The disclosure and the adviser’s large direct holding of 18,202,009 shares are material for governance transparency but represent routine director compensation and internal fund arrangements rather than a governance concern.
TL;DR Significant Fund ownership disclosed alongside director awards; this is a material ownership disclosure but not an event that alone alters company fundamentals.
The filing reports that after the transactions an indirect position of 28,815 shares is recorded and the Fund directly holds 18,202,009 shares. The grant of options at an $8.105 strike and expiration on 08/11/2030 is documented. These facts are relevant for share ownership calculations and insider holdings analysis. The parties expressly disclaim beneficial ownership beyond pecuniary interest, consistent with adviser-client arrangements disclosed in the footnotes.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Share Option (Right to Buy) | 76,200 | $0.00 | -- |
| Grant/Award | Ordinary Shares | 12,700 | $0.00 | -- |
| holding | Ordinary Shares | -- | -- | -- |
Footnotes (1)
- Dr. Kolchinsky was granted this restricted share unit award (RSU) pursuant to the 2025 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Issuer's 2026 annual general meeting or August 11, 2026. Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and options for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, or exercise of the options, as applicable, which will offset advisory fees owed by the Fund to the Adviser. RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein. Held directly by the Fund. Dr. Kolchinsky was granted this option pursuant to the 2025 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Issuer's 2026 annual general meeting or August 11, 2026.
